Oxford Gene Technology
News
OGT, Sanger to Co-develop Prenatal Microarray for Genetic Disorders - GenomeWeb News - January 31, 2007
Oxford Gene Technology and the Wellcome Trust Sanger Institute are working together to develop a microarray to test for prenatal genetic defects, OGT said today. The organizations will co-develop a commercial diagnostic that is expected to be faster and more cost-effective than current prenatal testing methods.
Under the agreement, OGT will use its ink jet in-situ synthesis platform to make a 60-mer oligonucleotide microarray, while Sanger will contribute clinical knowledge in targeting “the most appropriate syndromes,” OGT said.
INAL%2031.01.07.pdf" class="spip_out">Reference